The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial

PURPOSE: Nucleoside analogues form the backbone of many therapeutic regimens in oncology and require the presence of intracellular enzymes for their activation. A ProTide is comprised of a nucleoside fused to a protective phosphoramidate cap. ProTides are easily incorporated into cells whereupon the...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwenzer, Hagen, De Zan, Erica, Elshani, Mustafa, van Stiphout, Ruud, Kudsy, Mary, Morris, Josephine, Ferrari, Valentina, Um, In Hwa, Chettle, James, Kazmi, Farasat, Campo, Leticia, Easton, Alistair, Nijman, Sebastian, Serpi, Michaela, Symeonides, Stefan, Plummer, Ruth, Harrison, David J., Bond, Gareth, Blagden, Sarah P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401491/
https://www.ncbi.nlm.nih.gov/pubmed/34497073
http://dx.doi.org/10.1158/1078-0432.CCR-21-1652

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401491/
https://www.ncbi.nlm.nih.gov/pubmed/34497073
http://dx.doi.org/10.1158/1078-0432.CCR-21-1652

Ejemplares similares